Statements (65)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:drug
|
| gptkbp:bfsLayer |
3
|
| gptkbp:bfsParent |
gptkb:Pfizer
|
| gptkbp:accessories |
high demand during surges
|
| gptkbp:activities |
inhibits viral replication
|
| gptkbp:appointed_by |
oral tablets
|
| gptkbp:approves |
gptkb:U._S._Food_and_Drug_Administration
December 2021 |
| gptkbp:availability |
prescription only
|
| gptkbp:brand |
gptkb:Paxlovid
|
| gptkbp:clinical_trial |
Phase 2/3
NC T04381936 early treatment of COVID-19 significant reduction in hospitalization rates |
| gptkbp:contains |
gptkb:ritonavir
nirmatrelvir |
| gptkbp:contraindication |
severe renal impairment
|
| gptkbp:developed_by |
gptkb:Pfizer
|
| gptkbp:dosage_form |
tablets
|
| gptkbp:duration |
5 days
|
| gptkbp:education |
importance of adherence to regimen
|
| gptkbp:formulation |
fixed-dose combination
|
| gptkbp:healthcare |
reduces healthcare burden
|
| https://www.w3.org/2000/01/rdf-schema#label |
Paxlovid
|
| gptkbp:indication |
mild to moderate COVID-19
|
| gptkbp:ingredients |
nirmatrelvir/ritonavir
|
| gptkbp:interacts_with |
certain medications
CY P3 A4 inducers CY P3 A4 inhibitors |
| gptkbp:invention |
gptkb:Pfizer_Inc.
|
| gptkbp:is_a |
oral antiviral treatment
|
| gptkbp:is_effective_against |
reduces symptoms
|
| gptkbp:is_monitored_by |
renal function
|
| gptkbp:is_studied_in |
various clinical trials
|
| gptkbp:is_used_for |
treatment of COVID-19
treating COVID-19 |
| gptkbp:manager |
oral
|
| gptkbp:market |
gptkb:2021
|
| gptkbp:marketed_as |
gptkb:Paxlovid
|
| gptkbp:pharmacokinetics |
oral bioavailability
protease inhibitor |
| gptkbp:population |
adults and children over 12
|
| gptkbp:provides_information_on |
CDC recommendations
initiate as soon as possible |
| gptkbp:publishes |
peer-reviewed journals
|
| gptkbp:receives_funding_from |
government and private sectors
|
| gptkbp:reduces |
risk of hospitalization
risk of death |
| gptkbp:regulatory_compliance |
Emergency Use Authorization
|
| gptkbp:research_focus |
COVID-19 treatment efficacy
|
| gptkbp:safety_features |
post-marketing surveillance
generally well tolerated |
| gptkbp:side_effect |
nausea
diarrhea hypersensitivity reactions altered taste |
| gptkbp:storage |
room temperature
|
| gptkbp:student_enrollment |
positive COVID-19 test
|
| gptkbp:suitable_for |
high-risk patients
|
| gptkbp:supply_chain |
global distribution
|
| gptkbp:treatment |
improved recovery time
reduced viral load not for pre-exposure prophylaxis prevent progression to severe disease within 5 days of symptom onset |